中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Bariatric Embolization of Arteries for the Treatment of Obesity

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
Johns Hopkins University
合作者
Icahn School of Medicine at Mount Sinai

关键词

抽象

The purpose of this study is evaluate the safety and effectiveness of bariatric embolization as a minimally-invasive image-guided procedure for morbid obesity. In this procedure, specific blood vessels to the stomach are blocked in order to suppress some of the body's signals for feeling hungry, leading to weight loss.
Morbid obesity is currently treated with diet and exercise, medications, and surgery. This study is designed to help treat obesity using a minimally invasive, non-surgical, angiographic (through the blood vessel) approach. This procedure is similar to a common procedure used to treat bleeding within the stomach. This version of the procedure has been named "bariatric embolization".
Although there are over 40 hormones that limit food intake, there is only one hormone, ghrelin that has been shown to stimulate (prompt) food intake. In obese patients, eating fails to suppress ghrelin levels, which is believed to prevent feeling full after a meal and to lead to overeating. Due to the strong hunger craving effects of ghrelin, this hormone has been a target for the treatment of obesity and weight loss. More recently, ghrelin has been shown to have a significant role in the long-term effect of weight loss in bariatric (obesity) surgery where ghrelin levels are shown to be much lower when compared to untreated patients.
Recent data collected in animals in has shown that blocking blood vessels to a particular portion of the stomach (bariatric embolization) can temporarily decrease levels of the appetite inducing hormone ghrelin, and decrease short-term weight gain. In a study of 5 people, there was a decrease in ghrelin levels and weight loss in the first month after the procedure, but there is no information about the effects of the procedure over longer periods of time.
The investigator hopes to learn if bariatric embolization results in safe and effective weight loss in people who are morbidly obese.

日期

最后验证: 10/31/2018
首次提交: 06/10/2014
提交的预估入学人数: 06/12/2014
首次发布: 06/16/2014
上次提交的更新: 10/31/2018
最近更新发布: 11/04/2018
首次提交结果的日期: 09/23/2018
首次提交质量检查结果的日期: 10/31/2018
首次发布结果的日期: 11/04/2018
实际学习开始日期: 05/31/2014
预计主要完成日期: 11/30/2017
预计完成日期: 02/28/2018

状况或疾病

Morbid Obesity

干预/治疗

Device: Intervention/Bariatric Embolization

-

手臂组

干预/治疗
Experimental: Intervention/Bariatric Embolization
Device: Intervention/Bariatric Embolization
Embosphere Microspheres

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

1. Willing, able and mentally competent to provide written informed consent.

2. Body mass index (BMI) between 40-60.

3. Residence within 25 miles of the enrolling institution

4. Vascular anatomy (including celiac, hepatic, and gastric arteries) that in the opinion of the interventional radiologist amenable to Bariatric Embolization, as assessed on 3D CT angiography.

5. Suitable for protocol therapy as determined by the interventional radiology Investigator.

6. Adequate hematological, hepatic and renal function as follows:

Hematological Neutrophils > 1.5 x 109/L Platelets > 100 x 109/L International Normalized Ratio (INR) <1.5

Hepatic Bilirubin ≤ 2.0 mg/dL Albumin ≥ 2.5 g/L

Renal Estimated Glomerular Filtration Rate (GFR) > 60ml/min.1.73m2

7. Aged 18 years or older.

Exclusion Criteria:

1. Prior history of gastric pancreatic, hepatic, and/or splenic surgery

2. Prior radiation to the upper abdomen

3. Prior embolization to the stomach, spleen or liver

4. Portal venous hypertension

5. Prior or current history of peptic ulcer disease

6. Hiatal Hernia

7. Significant risk factors for peptic ulcer disease including daily NSAID use and smoking.

8. Active H. Pylori infection

9. Weight greater than 400 pound

10. Known aortic pathology such as aneurysm or dissection renal insufficiency as evidenced by an estimated glomerular filtration rate of < 60 milliliters per minute

11. Major comorbidity such as cancer, significant cardiovascular disease, diabetes, or peripheral arterial disease.

12. Complicated arterial anatomic variants including left gastric artery arising from the aorta, and/or hepatic arterial supply via a replaced or accessory left hepatic artery arising from the left gastric artery.

13. Pregnancy

14. Preexisting chronic abdominal pain

15. Positive stool occult study

16. Abnormal Endoscopy

17. Abnormal Nuclear Gastric Motility examination

18. American Society of Anaesthesiologists (ASA) Class 4 or 5 (very high risk surgical candidates: class 4= incapacitating disease that is a constant threat to life) at the time of screening for enrollment into the study will be excluded from participation. This exclusion criterion exists because of the possibility that surgical intervention will be needed if the study intervention subsequently leads to severe adverse effects.

19. History of Inflammatory Bowel Disease

20. Autoimmune disease

21. Cirrhosis

22. Known history of allergy to iodinated contrast media

结果

主要结果指标

1. Percent Weight Change [12 Months]

This will be assessed by Percentage of excess weight loss (EWL). Percentage of excess weight loss is calculated by measuring the participants excess weight at baseline and then calculating the percentage of excess weight that was lost 12 months after surgery (for example if a participant has 100 pounds of excess weight prior to surgery and loses 30 pounds, their excess weight loss would be 30%).

其他成果措施

1. Blood Pressure [12 Months]

Unit of Measure: mmHg

2. Lipid Panel [12 Months]

Unit of Measure: mg/dL, Total cholesterol, High-density lipoprotein cholesterol (HDL-C) - often called "good cholesterol" , Low-density lipoprotein cholesterol (LDL-C) - often called "bad cholesterol" and Triglycerides

3. Ghrelin Levels [12 Months]

Unit of Measure: pg/mL, Ghrelin on the other hand is a fast-acting hormone, seemingly playing a role in meal initiation.

4. Serum Obesity Hormone(Leptin) [12 Months]

This will be assessed by Leptin concentration Unit of Measure: pg/mL, Leptin is a mediator of long-term regulation of energy balance, suppressing food intake and thereby inducing weight loss.

5. Eating and Hunger/Satiety Assessments [12 Months]

Unit of Measure: N/A Utilizing 3-Factor Eating Questionnaire Scores

6. Quality of Life Parameters Survey [12 Months]

Unit of Measure: N/A Utilizing Short Form Health Survey (SF)-36 and Impact of Weight on Quality of Life (IWQOL)-Lite

7. Food Intake [12 Months]

Documented via journal entries

8. Results From Endoscopy [12 Months]

Photos and clinical reports analyzed

9. Gastric Motility/Emptying [12 Months]

Unit of Measure: (t 1/2) in minutes, A gastric emptying scan (GES) is a nuclear medicine exam that uses a radioactive material that you will eat in a meal. You will eat this meal in the Radiology department before your scan. The radioactive material allows doctors to see how your stomach empties. This scan is used to help diagnose conditions called motility disorders. These are conditions that change the way the stomach contracts and moves food into your intestines. A GES is a form of radiology, because radiation is used to take pictures of your body.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge